Pham Quang X sold $40K of CVKD
Pham Quang X (Chairman, CEO and Interim CFO) sold 11,444 shares of Cadrenal Therapeutics, Inc. (CVKD) at an average of $3.48 ($3.20–$3.55) across 2 trades over 2026-06-22 to 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider selling can be interpreted as negative sentiment, but 10b5-1 pre-arranged sales typically carry less informational content; the disclosed dollar value is modest.
Market read
Provides a fresh, primary-source datapoint on insider activity for CVKD, but with limited expected price impact given small size and 10b5-1 context.
What to watch
Traders may over-weight small insider sales; the more actionable signal would be whether there are concurrent operational catalysts (earnings, trial updates, financing) not present in this text.
Background
The article is an SEC EDGAR Form 4 insider transaction for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
SEC Form 4 shows CVKD CEO/Chairman/10% owner Pham Quang X sold 11,444 shares for ~$39.8K across 2026-06-22 to 2026-06-23 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this sale; any impact would be sentiment-driven and short-lived.
The filing is a primary-source insider transaction, but the disclosed size (~$40K) is small relative to typical market caps and is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPham Quang X
Chairman, CEO, Interim CFO; reported open-market sale under a 10b5-1 plan.
